| Title： | Metabolic dysfunction-associated fatty liver disease and risk of CKD |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Comprehensive guideline |
| Countries and regions： | China |
| Guidelines users： | Clinicians, nurses and technicians engaged in liver disease and renal disease in hospitals |
| Evidence classification method： | Grading of recommendations assessment, development and evaluation |
| Development unit： | panel of International experts and CHESS-MAFLD collaboration |
| Registration time: | 2022-06-22 |
| Registration number： | IPGRP-2022CN359 |
| Purpose of the guideline: | Management and treatments provide a framework for the development of appropriate guidance on CKD in patients with MAFLD |
Latest registration
